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ABSTRACT
Background
In melanoma, morphology-based classification systems have not been able to provide
relevant information for selecting treatments for patients whose tumors have metastasized.
The recent identification of causative genetic alterations has revealed mutations in signaling
pathways that offer targets for therapy. Identifying morphologic surrogates that can identify
patients whose tumors express such alterations (or functionally equivalent alterations) would
be clinically useful for therapy stratification and for retrospective analysis of clinical trial data.
Methodology/Principal Findings
We defined and assessed a panel of histomorphologic measures and correlated them with
the mutation status of the oncogenes BRAF and NRAS in a cohort of 302 archival tissues of
primary cutaneous melanomas from an academic comprehensive cancer center. Melanomas
with BRAF mutations showed distinct morphological features such as increased upward
migration and nest formation of intraepidermal melanocytes, thickening of the involved
epidermis, and sharper demarcation to the surrounding skin; and they had larger, rounder, and
more pigmented tumor cells (all p-values below 0.0001). By contrast, melanomas with NRAS
mutations could not be distinguished based on these morphological features. Using simple
combinations of features, BRAF mutation status could be predicted with up to 90.8% accuracy
in the entire cohort as well as within the categories of the current World Health Organization
(WHO) classification. Among the variables routinely recorded in cancer registries, we identified
age , 55 y as the single most predictive factor of BRAF mutation in our cohort. Using age , 55
y as a surrogate for BRAF mutation in an independent cohort of 4,785 patients of the Southern
German Tumor Registry, we found a significant survival benefit (p , 0.0001) for patients who,
based on their age, were predicted to have BRAF mutant melanomas in 69% of the cases. This
group also showed a different pattern of metastasis, more frequently involving regional lymph
nodes, compared to the patients predicted to have no BRAF mutation and who more
frequently displayed satellite, in-transit metastasis, and visceral metastasis (p , 0.0001).
Conclusions
Refined morphological classification of primary melanomas can be used to improve existing
melanoma classifications by forming subgroups that are genetically more homogeneous and
likely to differ in important clinical variables such as outcome and pattern of metastasis. We
expect this information to improve classification and facilitate stratification for therapy as well
as retrospective analysis of existing trial data.
The Editors’ Summary of this article follows the references.
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Cutaneous melanomas can vary signiﬁcantly in their
clinical and histopathological appearance, which has lead to
the development and reﬁnement of morphologically based
classiﬁcation systems. The current World Health Organiza-
tion (WHO) classiﬁcation of skin tumors [1], which is an
extension of the revised Sydney classiﬁcation from 1986 [2–4],
distinguishes four main types of melanoma; superﬁcial
spreading melanoma (SSM), lentigo maligna melanoma
(LMM), nodular melanoma (NM), and acral lentiginous
melanoma (ALM). These distinctions are based on the
observation that certain combinations of morphological
features of the microscopic growth pattern of melanoma
during its early progression phase are associated with clinical
features such as anatomic site of the primary tumor, pace of
tumor evolution, and patient age. Although these proposed
categories undoubtedly represent prototypical instances or
archetypes of the clinical and histopathological presentations
that are valuable for teaching purposes, their impact on
clinical management has been limited. A major reason is that
no signiﬁcant difference in overall survival or treatment
responses could be demonstrated between the categories
when tumors of equivalent tumor thickness were compared
or after metastasis had occurred [5]. Furthermore, these
subtypes are deﬁned by multiple criteria, each assessing
complex morphological patterns, resulting in a wide range of
possible presentations. Thus a considerable portion of
melanomas are differentially classiﬁed by multiple observers,
or are classiﬁed as ‘‘ambiguous’’ [6]. Some have questioned
the existence of biologically distinct melanoma types alto-
gether, proposing that the morphological differences are
entirely secondary to the anatomic site in which the tumor
arises [7], or, in the case of NM, are a consequence of
differences in the pace of tumor evolution [8].
In order to establish whether a disease is composed of
distinct subtypes it is necessary to integrate clinicopatho-
logical features with the underlying biologic factors and
identify disease groups that are homogeneous in their
etiology, clinical behavior, and management requirements.
These subtypes, if found, would then form the basis of a
clinically useful classiﬁcation system. In cancer, genetic
alterations can serve as biomarkers for classiﬁcation pur-
poses, in particular if they are causally linked to the disease
process. With the advent of therapeutics targeted to genes
and signaling pathways, these oncogenic mutations are
gaining direct importance for clinical management. But
knowledge of the critical constitutional and somatic genetic
factors is currently incomplete. Since the clinical character-
istics of a tumor must be, at least in part, genetically
determined, elucidation of the phenotypic consequences of
currently known genetic factors will reveal aspects of their
function and highlight gaps in knowledge, which may guide
future discovery. More immediately, clinicopathological
features that are associated with speciﬁc genetic factors
provide an attractive basis on which to build a reﬁned
classiﬁcation system that is practical to implement and useful
for patient management.
Recently, we described distinct patterns of chromosomal
aberrations and mutations in oncogenes such as BRAF and
KIT that correlated more with the site of the primary tumor
and the degree of chronic sun-induced damage of the
surrounding skin than with the traditional melanoma types
[9–13]. Epidemiological studies have independently empha-
sized the impact of chronic sun exposure on the mole count
and survival time of melanoma patients [14,15]. Together,
these ﬁndings strongly support the existence of distinct
melanoma subtypes, but also indicate that these are insufﬁ-
ciently captured by the existing classiﬁcation system. Using
previously recognized morphological features of primary
melanoma, we performed a detailed phenotypic character-
ization of a large cohort of primary melanomas and
correlated those features with the mutation status of BRAF
and NRAS, the most commonly mutated oncogenes known in
melanoma. Speciﬁcally, we deﬁned simple histomorphologic
features that can be reproducibly scored in routinely stained
sections.
Methods
Tumor Specimens and Mutation Analysis
A total of 302 cases of primary cutaneous melanoma that
have been part of previous genetic analyses were included in
this study [12,16]. BRAF mutation data of exon 15, which
includes codon 600, were available from all samples. NRAS
mutation data of exons 1 and 2 for samples were available
from a previously published subset of the samples [12], and
were obtained for the remainder of the cases using our
standard protocols [17]. For all cases, NRAS was only analyzed
in melanomas in which no BRAF exon 15 mutations were
found because earlier studies indicated a very low rate of
cooccurrence of these aberrations.
Histopathological Analysis
All histopathological evaluations were carried out on
routinely stained HE sections, processed through the UCSF
Dermatopathology Service. Cases were classiﬁed into SSM,
LMM, NM, and, ALM according to the WHO classiﬁcation, or
not classiﬁable (NC) if they did not ﬁt unequivocally in any of
these categories [2,3,18]. The cases were also classiﬁed into
acral melanoma, and melanoma arising on skin with or
without evidence of chronic sun-induced damage (CSD and
non-CSD, respectively), as described previously [12].
Analysis of Elementary Histological Features
All sections of tissue that were available for each specimen
were examined, and a semiquantitative assessment of each
histological feature for a tumor was obtained from the
combined analysis of all of the sections. Except where stated
otherwise, the morphologic assessments were made in areas
of radial growth, excluding areas of vertical growth. Radial
growth phase (RGP) and vertical growth phase (VGP) were
deﬁned as described by Clark and Elder [19]. For melanomas
that were classiﬁed as NMs in the WHO classiﬁcation
applying the three-rete ridge rule, the assessment was made
in any small intraepidermal component adjacent to the
nodular portion wherever possible. NMs without a small
adjacent intraepidermal component were not assessed for
these features. The histological features examined were as
follows.
Upward scatter of intraepidermal melanocytes. The pro-
portion of intraepidermal melanocytes present above the
basal layer, irrespective of whether suprabasal melanocytes
were arranged singly or as nests, was graded from 0 to 3
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Morphogenetic Correlation of Melanoma(Figure 1A) using the following criteria: 0, essentially all
melanocytes situated at the dermo-epidermal junction, with
only rare melanocytes in higher epidermal layers; 1, the
majority of melanocytes (75%–100%) situated at the dermo-
epidermal junction, with some present in higher epidermal
layers; 2, roughly equal proportions of intraepidermal
melanocytes present at the dermo-epidermal junction and
in higher epidermal layers; 3, most (.50%) of the intra-
epidermal melanocytes situated in the upper layers of the
epidermis
Nest formation of intraepidermal melanocytes. Intraepi-
dermal melanocytes were deﬁned as arranged in nests rather
than single cells if they formed clusters of ﬁve or more cells
no matter where they were located, e.g., whether within the
basal epidermis or in higher layers of the epidermis (Figure
1B). The degree of nesting was quantiﬁed as: 0, intra-
epidermal melanocytes present almost exclusively as single
cells with only rare nests; 1, intraepidermal melanocytes
predominantly arranged as single cells with no more than
25% of cells in nests; 2, 25%–50% of the intraepidermal
melanocytes in nests; 3, .50% of the intraepidermal
melanocytes in nests.
Pigmentation of melanocytes. Pigmentation was deﬁned as
melanin accumulation within the constituent melanocytes
and was scored on a ﬁve-point scale using 203 and 403
objectives (Figure 1C). Melanophages were not considered.
Pigmentation was assessed in three different ways: maximum
pigmentation anywhere in the tumor; average pigmentation
across all sections of the RGP; and average pigmentation
across all sections of the vertical growth phase (VGP). These
Figure 1. Grading of Morphological Features
(A) Scatter of intraepidermal melanocytes.
(B) Nesting of intraepidermal melanocytes.
(C) Cytoplasmic pigmentation of neoplastic melanocytes.
(D) Cell shapes.
doi:10.1371/journal.pmed.0050120.g001
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so we standardized on using the maximum pigmentation
scored anywhere in the tumor. Pigmentation was scored from
0–4 using the scale: 0, (absent) no pigment discernible even at
high power; 1, (faint) pigmentation barely visible at low
power. At high power, melanocytes showed a faint diffuse
melanin pigment or a few pigment granules. 2, (moderate)
pigmentation visible at low power with translucent cytoplasm
that is signiﬁcantly lighter than the hematoxylin stained
nuclei; 3, (high) pigmentation easily visible at low power with
the cytoplasmic pigmentation reaching an intensity approx-
imating that of the nucleus; 4, (very high) cytoplasm strikingly
pigmented making it difﬁcult to identify nuclei.
Epidermal contour. The contour of the epidermis involved
by the RGP of the melanoma was compared to the adjacent
normal epidermis (Figure S1A) and scored from 0 to 4: 0,
(atrophic) markedly thinned epidermis with effacement of
rete ridges; 1, (thinned) thinned epidermis with partial
attenuation of rete ridges; 2, (normal) epidermal silhouette
similar to the adjacent uninvolved epidermis; 3, (thickened)
slight to moderate epidermal hyperplasia with elongation of
the rete ridges resulting in a maximum 2-fold increase in
epidermal thickness; 4, (hyperplastic) marked epidermal
hyperplasia resulting in a greater than 2-fold increase in
epidermal thickness.
Lateral circumscription. Lateral circumscription was as-
sessed by examining the transition of the intraepidermal
growth portion of the tumor to normal skin at the tumor
periphery. The area with the most gradual transition in any of
the tissue pieces (Figure S1B) was scored from 0 to 2. 0,
(discontinuous) areas of apparently uninvolved epidermis
interspersed with tumor. Areas of uninvolved epidermis
apparently caused by regression were considered tumor; 1,
(gradual but continuous) continuous decrease of the number
of intraepidermal melanocytes making it difﬁcult to pinpoint
the transition to normal skin to within one or two rete ridges
or 0.1 mm; 2, (abrupt) transition from involved epidermis to
the adjacent normal skin easily determined within one or two
rete ridges or 0.1 mm.
Solar elastosis. The degree of solar elastosis was classiﬁed
on an 11-category scale ranging from 0 to 3þ by examining
the normal skin surrounding the melanoma using the 103
and 203 lenses, as described previously [16].
Size and shape of cells, nuclei, and nucleoli. Size and shape
of tumor cells and their nuclei were assessed in the most
cellular portion of the tumor using a 203lens. Nuclei of small
lymphocytes, which we determined ranged in size from 4 to 5
lm, were used as a size reference. Visual assessment of size
was quantiﬁed on a scale from 1 to 3. Tumor cells were
considered 1, small; 2, medium; or 3, large, if the greatest
diameter was ,8 lm, between 8 and 10 lm, and .10 lm,
respectively (Figure S1C). Similarly, nuclei were considered 1,
small; 2, medium; and 3, large, if the greatest diameter was ,5
lm, between 5 and 6 lm, and .6 lm. Nucleolar size was
assessed in the most cellular portion of the tumor using a 403
lens: 1, (small) nucleoli of tumor cells smaller than those of
keratinocytes, or not discernible; 2, (medium) tumor nucleoli
comparable in size to those of keratinocytes; 3, (large) tumor
nucleoli larger than those of keratinocytes.
Cell shape was visually assessed at 203 in the most cellular
portion of the tumor using (Figure 1D). The visual assessment
graded the cells from 0 to 3: 0, (round) long and short
diameters approximately equal; 1, (ovoid) long diameter
approximately one-third greater than the short diameter; 2,
(elongated) long diameter between one-third and two times
longer than the short diameter; 3, (spindled) long diameter
.two times the short diameter.
Sizes and shapes of cells were also determined quantita-
tively in 264 samples of the cohort using photomicrographs
taken with a 203lens and averaging ten random cells within a
representative area (Table S2). Sizes were expressed as the
product of the long and short diameter (l
2), and shapes as
their ratio. Quantitative and visual measurements showed
good agreement (Kendall’s Tau Test 0.4–0.6) (Table S3). The
visual assessments were used in the analysis, as discussed
below.
Ulceration. Ulceration was deﬁned as the presence of a full-
thickness epidermal defect; evidence of host response (i.e.,
ﬁbrin deposition, neutrophils); and thinning, effacement, or
reactive hyperplasia of the surrounding epidermis [20].
Thickness. Tumor thickness was measured in millimeters
according to Breslow [21].
Statistical Analysis
The univariate analyses for binary outcomes (e.g., BRAF
mutation present or not) were performed by ﬁtting a logistic
regression with each of the measurements. Standard error of
the odds ratio (OR) was determined using the Taylor
expansion rule. All ordinal measurements of the phenotypic
characteristics were treated as scores in the analyses after
testing for linearity of the scores with respect to each
outcome. Where nonlinear, the polynomials of higher order
were ﬁtted to correct nonlinearity according to the default
approach to treatment of ordinal variables. Continuous
variables (thickness, cell size, cell shape, nuclear size, and
nuclear shape) were preprocessed by adding one-tenth of the
smallest nonzero value of the respective variable followed by
taking log10 of the values to render their distribution more
normal. The unordered categorical variables (anatomic site,
WHO type, non-CSD, CSD, Acral grouping [11], and gender)
were treated as factor variables in logistic regression. Multi-
variate analyses to predict mutation status were performed
using single binary classiﬁcation tree classiﬁers [22], Random
Forests [23], and multivariate logistic regression. A detailed
description of the methods is provided in the Text S1. All
statistical analyses were conducted using the freely available R
statistical language.
Results
Morphometric Analysis of Phenotypic Features
Clinical information, BRAF mutation status, and WHO
classiﬁcations of all 302 primary cutaneous melanomas in this
study are summarized in Table 1. The phenotypic character-
istics that we focused on in our measurements comprised
‘‘elementary’’ features that mostly are combined in various
ways in the WHO classiﬁcation. For example, in the WHO
classiﬁcation the features ‘‘lentiginous’’ and ‘‘pagetoid’’
growth are prominently used as opposing ends of a spectrum
of intraepidermal growth. However, both lentiginous and
pagetoid are ‘‘complex’’ patterns composed of several
separable features including (a) whether the neoplastic
melanocytes are scattered throughout all layers of the
epidermis (in pagetoid) or are situated in the basal layer (in
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nests (in pagetoid) or predominantly as single units (in
lentiginous); and (c) whether the melanocytes are enlarged
and round (in pagetoid) or small with scalloped contours or
spindled (in lentiginous). Therefore to describe intraepider-
mal growth we deﬁned and assessed features termed: scatter,
nest formation, size and shape (Figure 1). Similar to the WHO
classiﬁcation, we focused our evaluation of the features
primarily on the early progression phases, e.g., the RGP of the
tumor in the expectation that this would be the most
informative regarding its ‘‘histogenetic’’ origin.
All features were visually scored in the 302 tumors by one
of us (AV). Interobserver agreement was determined by
having an additional observer (JB) score a randomly selected
subset of 50 cases. The scorers were blinded to knowledge of
the genetic status of the tumors until the scoring was
complete. Kappa statistics [24] indicated moderate to
excellent agreement (Table S4). Table 2 shows the number
of tumors by phenotypic feature and mutation status. Figure
2 shows a heatmap of features by mutation status (Figure 2A)
and by the WHO subtypes (Figure 2B).
BRAF, but Not NRAS, Mutation Status Is Strongly Related
to Some Phenotypic Features
Tables 3 and S5 show the results of univariate analysis to
determine the association statistic between the elementary
phenotypes and mutation status. Several are highly signiﬁ-
cant. Since most of the features are assessed as ordinal
variables, the ORs reﬂect the increase (or decrease) of the
odds per unit increment. For example in the comparison of
nesting between melanomas with and without BRAF muta-
tions (ﬁrst column), the OR of 3.11 indicates the increase in
odds for one increment of the ordinal scale for scatter (e.g.,
nesting 1 to nesting 2). To calculate the odds for an increment
of two the indicated OR should be squared. Compared to
melanomas without BRAF mutations, melanomas with BRAF
mutations showed statistically signiﬁcantly higher degrees of
intraepidermal scatter of melanocytes, and a higher propor-
tion of melanocytes arranged in nests. In addition, the
epidermis of the RGP of melanomas with BRAF mutations
was more commonly thickened compared to the surrounding
skin, i.e., the score for the ‘‘epidermal contour’’ had a higher
average value, and the transition from the tumor into the
surrounding skin tended to be more abrupt than in
melanomas without BRAF mutations, i.e., ‘‘lateral circum-
scription’’ had a higher average score. Furthermore, the
tumor cells of BRAF-mutated melanomas were larger, had a
rounder shape, and showed a higher degree of pigmentation
than cells in tumors without BRAF mutations. As we reported
previously [16], melanomas with BRAF mutations also had a
lower degree of solar elastosis in the surrounding skin than
melanomas without BRAF mutations.
Given the signiﬁcant univariate correlations, we employed
several multivariate statistical approaches to deﬁne the most
powerful combinations of variables for prediction of muta-
tion status. These analyses produced a consistent set of
variables that included the morphological features pigmen-
tation, upward scatter, nesting of intraepidermal melano-
cytes, and cell shape. In addition, a younger age at diagnosis
was independently associated with BRAF mutation status
(Table S6). The results of the multivariate analyses are most
intuitively displayed using a binary classiﬁcation tree since it
deﬁnes a decision structure using speciﬁc thresholds for
individual characteristics at each node. Classiﬁcation trees
developed using all clinical and morphologic variables
correctly predicted BRAF mutation status with up to 82%
accuracy if one required a prediction for all tumors.
Classiﬁcation trees with high prediction accuracy also formed
Table 1. Clinical Characteristics of Patients and Melanomas by Mutation Status of BRAF and NRAS Included in Our Analysis
Clinical Characteristics Category n (%) BRAF Mutation, n (%) NRAS Mutation n (%) Neither Mutation n (%)
WHO subtype SSM 189 (62.6) 98 (51.9) 36 (19) 55 (29.1)
LMM 39 (12.9) 13 (33.3) 4 (10.3) 22 (56.4)
ALM 23 (7.6) 3 (13) 2 (8.7) 18 (78.3)
NM 16 (5.3) 11 (68 8) 2 (12.5) 3 (18.7)
NC 35 (11.6) 17 (48 6) 6 (17.1) 12 (34.3)
Total 302 (100) 142 (47) 50 (16.6) 110 (36.4)
Acral, CSD, non-CSD grouping Non-CSD 152 (50.3) 96 (63 1) 27 (17.8) 29 (19.1)
CSD 106 (35.1) 33 (31 1) 17 (16.1) 56 (52.8)
Acral 40 (13.2) 10 (25) 5 (12.5) 25 (62.5)
NC 4 (1.3) 3 (75) 1 (25) 0
Total 302 (100) 142 (47) 50 (16.6) 110 (36.4)
Anatomic site Face/Scalp 48 (15.9) 14 (29.2) 5 (10.4) 29 (60.4)
Trunk 114 (37.7) 72 (63.2) 17 (14.9) 25 (21.9)
Upper Ext 37 (12.3) 13 (35.1) 10 (27.1) 14 (37.8)
Lower Ext 52 (17.2) 28 (53.8) 12 (23.1) 12 (23.1)
Acral 35 (11.6) 8 (22.9) 4 (11.4) 23 (65.7)
Total 286 (94.7) 135 (47.2) 48 (16.8) 103 (36)
Sex Female 128 (42.4) 69 (53.9) 21 (16.4) 38 (29.7)
Male 154 (51) 66 (42.8) 24 (15.6) 64 (41.6)
Total 282 (93.4) 135 (47.9) 45 (15.9) 102 (36.2)
Age (y) — 59.5 (26)
a 51 (24.5)
a 63 (25.5)
a 66 (18)
a
Thickness (mm) — 1.2 (2.4)
a 1 (1.7)
a 1.1 (1.6)
a 1.6 (2.8)
a
Values are expressed as n (%) unless otherwise noted. Total percentages that do not add up to 100% have missing values.
aMedian and interquartile range.
doi:10.1371/journal.pmed.0050120.t001
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Figure 3A shows one such tree, which has 76% accuracy for
predictions for all samples. However, it is clear that some
branches of the tree lead to much stronger predictions than
others. Thus tumors without ‘‘upward scatter’’ have a very low
probability of being BRAF mutant, while those with ‘‘scatter’’
. 0 and ‘‘nesting’’ . 2 are almost all BRAF mutant. However,
tumors with ‘‘scatter’’ . 0 but lower ‘‘nesting’’ have about
equal chance of being BRAF wild-type (47%) or mutant
(53%), with high ‘‘pigmentation’’ increasing the odds of being
mutant to 70%.
Although intuitive to interpret, single classiﬁcation trees
are inherently unstable in the sense that slight perturbations
in the dataset used for tree building may lead to large changes
in the tree topology, e.g., several trees with approximately the
same discrimination power can be found. Resampling-based
algorithms are well-known solutions for improving the
accuracy of single classiﬁcation trees. We used the Random
Forest classiﬁer, a method that grows many classiﬁcation
trees, each based on a different subset containing on average
66% of the samples. The resulting collection of individual
trees is referred to as ‘‘random forest.’’ The ﬁnal prediction
for each sample is the outcome of the majority vote of those
trees in the forest that did not include that sample in their
Table 2. Morphologic Features of Melanomas by Mutation Status of BRAF and NRAS Included in Our Analysis
Morphological Characteristics Category n (%) BRAF Mutation, n (%) NRAS Mutation, n (%) Neither Mutation, n (%)
Scatter Absent 71 (23.5) 3 (2.1) 22 (44) 46 (41.8)
Slight 112 (37.1) 59 (41.6) 18 (36) 35 (31.8)
Medium 54 (17.9) 36 (25.3) 5 (10) 13 (11.8)
Prominent 31 (10.2) 26 (18.3) 0 5 (4.61)
Total assessable 268 (88.7) 124 (87.3) 45 (90) 99 (90)
Pigmentation Absent 56 (18.5) 12 (8.4) 9 (18) 35 (31.8)
Slight 63 (20.9) 18 (12.7) 18 (36) 27 (24.5)
Medium 76 (25.2) 37 (26.1) 11 (22) 28 (25.5)
High 59 (19.5) 38 (26.8) 7 (14) 14 (12.7)
Very high 42 (13.9) 34 (23.9) 2 (4) 6 (5.5)
Total assessable 296 (98) 139 (97.9) 47 (94) 110 (100)
Nesting Absent 32 (10.6) 0 9 (18) 23 (20.9)
Slight 59 (19.5) 20 (14.1) 11 (22) 28 (25.5)
Medium 81 (26.8) 32 (22.5) 12 (24) 37 (33.6)
Prominent 96 (31.8) 72 (50.7) 13 (26) 11 (10)
Total assessable 268 (88.7) 124 (87.3) 45 (90) 99 (90)
Circumscription Abrupt 122 (40.4) 79 (55.7) 14 (28) 29 (26.4)
Continuous 90 (29.8) 34 (23.9) 18 (36) 38 (34.6)
Discontinuous 31 (10.3) 5 (3.5) 10 (20) 16 (14.5)
Total assessable 243 (80.5) 118 (83.1) 42 (84) 83 (75.5)
Epidermal contour Atrophy 6 (2) 0 2 (4) 4 (3.6)
Effacement 28 (9.3) 11 (7.8) 6 (12) 11 (10)
Normal 41 (13.6) 16 (11.2) 8 (16) 17 (15.5)
Thickening 104 (34.4) 53 (37.3) 18 (36) 33 (30)
Hyperplasia 82 (27.1) 41 (28.9) 10 (20) 31 (28.2)
Total assessable 261 (86.4) 121 (85.2) 44 (88) 96 (87.3)
Solar elastosis [1–11] — 6( 4 )
a 5 (3)
a 6( 4 )
a 7( 3 )
a
Cell size
b Small 141 (46.7) 53 (37.3) 34 (68) 54 (49)
Medium 117 (38.7) 67 (47.2) 11 (22) 39 (35.5)
Large 38 (12.6) 21 (14.8) 4 (8) 13 (11.8)
Total assessable 296 (98) 141 (99.3) 49 (98) 106 (96.4)
Cell shape
b Round 197 (65.2) 110 (77.5) 29 (58) 58 (52.7)
Ovoid 45 (14.9) 16 (11.3) 8 (16) 21 (19.1)
Elongated 35 (11.6) 11 (7.7) 7 (14) 17 (15.5)
Spindled 19 (6.3) 4 (2.8) 5 (10) 10 (9.1)
Total assessable 296 (98) 141 (99.3) 49 (98) 106 (96.4)
Nuclear size
b Small 200 (66.2) 87 (61.3) 39 (78) 74 (67.3)
Medium 87 (28.8) 49 (34.5) 10 (20) 28 (25.5)
Large 8 (2.6) 4 (2.8) 0 4 (3.6)
Total assessable 295 (97.7) 140 (98.6) 49 (98) 106 (96.4)
Nuclear shape [0–1] — 0.74 (0.16)
a 0.76 (0.1)
a 0.69 (0.25)
a 0.71 (0.2)
a
Nucleolar size Small 60 (19.9) 24 (16.9) 10 (20) 26 (23.6)
Medium 145 (48) 77 (54.2) 22 (44) 46 (41.8)
Large 96 (31.8) 41 (28.9) 18 (36) 37 (33.7)
Total assessable 301 (99.7) 142 (100) 50 (100) 109 (99.1)
Ulceration Yes 94 (31.1) 40 (28.2) 12 (24) 42 (38.2)
No 201 (66.6) 100 (70.4) 36 (72) 65 (59.1)
Total assessable 295 (97.7) 140 (98.6) 48 (96) 107 (97.3)
Values are expressed as n (%) unless otherwise noted. Total percentages that do not add up to 100% have missing values.
aMedian and interquartile range.
bVariables for which continuous measurements were also assessed (Table S2).
doi:10.1371/journal.pmed.0050120.t002
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Morphogenetic Correlation of Melanomadevelopment. The unbiased estimate of the error is given by
1, prediction accuracy [23,25]. As expected, random forests
signiﬁcantly improved the classiﬁcation performance, cor-
rectly predicting BRAF status with 91.8% accuracy using all
variables, and 87% using morphological variables only. In
comparison, the probability for predicting BRAF mutation in
this dataset by chance is about 50%. Thus the conventional
morphological parameters of a tumor are substantially
affected by BRAF mutations. The performances of the
different classiﬁcation approaches we applied are summar-
ized in Table S6.
While the elementary morphological characteristics that
contribute to the WHO classiﬁcation system have a very
strong relationship to BRAF mutation status, the WHO
Figure 2. Heatmap of Features by Mutation Status (A) and by WHO Subtypes (B)
Variables significantly associated with BRAF. Samples are in columns, variables in rows. The scores range from shades of blue (low score), to gray
(intermediate scores), to yellow (high scores). Samples are ordered within each category using agglomerative hierarchical clustering on morphological
variables by Euclidean distance and Ward’s criterion. Ac, acral; CSD, chronic sun damage as defined in [12]; H, head; LE, lower extremity; Tr, trunk; UE,
upper extremity;.
doi:10.1371/journal.pmed.0050120.g002
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Morphogenetic Correlation of Melanomacategories were not independently associated with BRAF
mutation status since mutations are found in considerable
proportions of all WHO categories, with the exception of
ALM, Table 1, and Figure 2. The strong relationship of the
elementary characteristics to mutation status is emphasized
by the fact that the same associations remained signiﬁcant
when the analyses were restricted to individual WHO
categories, where the proportion of mutations ranged from
13% in the Acral category to 52% in the SSM category (Table
S7). These ﬁndings suggest that the elementary features can
be combined to a reﬁned classiﬁcation algorithm yielding
melanoma groups that are more homogeneous with regard to
their underlying genetic alterations.
In contrast to BRAF, a different, much smaller, set of
signiﬁcant criteria was found in univariate comparisons
between melanomas with NRAS mutations and melanomas
with mutations in neither BRAF nor NRAS (Tables 3 and S2).
However, the single tree classiﬁer did not produce any
signiﬁcant splits indicating that the power of these variables
to predict NRAS mutation status was limited.
We did not have sufﬁcient outcome information of the
patients in our cohort to test for differences between the
melanoma groups formed by the classiﬁcation tree of Figure
3A. Since none of the morphological features assessed in our
study is currently recorded in any tumor registry we also
could not readily apply this approach to existing clinical
cohorts. However, gender, patient age, WHO subtype, site of
primary tumor, tumor thickness, and presence or absence of
ulceration are routinely recorded in registries. Using these
variables only on our data, a classiﬁcation tree consisting of a
stump (a tree with only two terminal nodes) was formed with
age as the sole criterion for predicting BRAF status. Using this
tree 69% of the melanomas in patients under the age of 55 y
had BRAF mutant tumors, while only 35.3 % were BRAF
mutant in older patients (Figure 3B). Applying this age cutoff
to a cohort of 4,785 patients from the German Melanoma
Registry [26] signiﬁcant differences in disease-speciﬁc overall
survival and disease-free survival were found (Figure 3B). In
multivariate analysis, this age cutoff was associated with
outcome independent of tumor thickness, anatomic site, and
Table 3. Comparison of Morphological Variables Depending on the Mutation Status of BRAF and NRAS
Criteria Category BRAF Mutant Versus
BRAF Wild-Type
BRAF Mutant Versus
Neither Mutant
BRAF Mutant Versus
NRAS Mutant
NRAS Mutant Versus
Neither
OR (CI 95%) p-Value OR (CI 95%) p-Value OR (CI 95%) p-Value OR (CI 95%) p-Value
Scatter Linear
a 27.95 (10.10–77.37) ,0.0001 21.08 (7.55–58.77) ,0.0001 8.1 (3.81–17.1) ,0.0001 0.79 (0.5–1.25) 0.32
Quadratic
a 0.32 (0.14–0.73) 0.007 0.27 (0.12–0.63) 0.002
Cubic
a 1.96 (1.12–3.45) 0.02 1.91 (1.04–3.52) 0.038
Pigmentation — 2.01 (1.63–2.48) ,0.0001 2.01 (1.61–2.52) ,0.0001 1.94 (1.44–2.61) ,0.0001 1.09 (0.81–1.45) 0.58
Nesting — 3.11 (2.27–4.27) ,0.0001 3.68 (2.55–5.31) ,0.0001 2.44 (1.65–3.61) ,0.0001 1.32 (0.93–1.88) 0.13
Circumscription — 3.06 (2.01–4.67) ,0.0001 2.99 (1.88–4.75) ,0.0001 3.25 (1.87–5.64) ,0.0001 0.89 (0.54–1.48) 0.66
Epidermal contour — 1.3 (1.02–1.66) 0.031 1.25 (0.96–1.63) 0.098 1.47 (1.04–2.07) 0.028 0.89 (0.65–1.21) 0.45
Solar elastosis — 0.89 (0.81–0.97) 0.006 0.88 (0.8–0.96) 0.006 0.88 (0.77–1.02) 0.08 0.97 (0.87–1.08) 0.6
Cell size — 1.63 (1.16–2.28) 0.004 1.4 (0.97–2.03) 0.08 2.51 (1.44–4.38) 0.001 0.59 (0.34–1.02) 0.06
Cell shape — 0.58 (0.44–0.76) ,0.0001 0.57 (0.42–0.77) 0.0002 0.61 (0.43–0.87) 0.006 0.96 (0.69–1.33) 0.79
Nuclear size — 1.48 (0.96–2.29) 0.076 1.26 (0.79–2.01) 0.34 2.39 (1.14–5.02) 0.02 0.56 (0.27–1.18) 0.13
Nuclear shape
b — 1.66 (1.23–2.25) 0.001 1.63 (1.16–2.27) 0.004 1.51 (1.05–2.17) 0.02 0.96 (0.67–1.38) 0.82
Nucleolar size — 1 (0.73–1.4) 0.99 1.04 (0.73–1.48) 0.83 0.92 (0.57–1.47) 0.72 1.11 (0.71–1.74) 0.64
Ulceration — 0.75 (0.46–1.23) 0.25 0.62 (0.36–1.06) 0.07 1.2 (0.57–2.54) 0.63 0.52 (0.24–1.1) 0.08
WHO subtype SSM 1 (Reference) ,0.0001 1 (Reference) ,0.0001 1 (Reference) 0.84 1 (Reference) 0.02
LMM 0.46 (0.23–0.96) 0.037 0.33 (0.15–0.71) 0.004 1.19 (0.37–3.9) 0.77 0.28 (0.09–0.87) 0.03
ALM 0.14 (0.04–0.48) 0.002 0.09 (0.03–0.33) 0.0002 0.55 (0.09–3.43) 0.52 0.17 (0.04–0.78) 0.02
NM 2.04 (0.68–6.11) 0.2 2.06 (0.55–7.69) 0.28 2.02 (0.43–9.56) 0.38 1.02 (0.16–6.4) 0.98
NC 0.88 (0.43–1.8) 0.72 0.8 (0.35–1.79) 0.58 1.04 (0.38–2.85) 0.94 0.76 (0.26–2.22) 0.62
Acral, CSD,
non-CSD Grouping Non-CSD 1 (Reference) ,0.0001 1 (Reference) ,0.0001 1 (Reference) 0.38 1 (Reference) 0.002
CSD 0.26 (0.16–0.45) ,0.0001 0.18 (0.1–0.32) ,0.0001 0.55 (0.26–1.13) 0.1 0.33 (0.15–0.69) 0.004
Acral 0.19 (0.09–0.43) ,0.0001 0.12 (0.05–0.28) ,0.0001 0.56 (0.18–1.79) 0.33 0.21 (0.07–0.64) 0.006
NC 1.75 (0.18–17.23) 0.63 1,739,339 (0–‘) 0.99 0.84 (0.08–8.44) 0.89 2,275,082 (0–‘) 0.99
Gender Female 1 0.06 1 0.03 1 0.61 1 0.28
Male 0.64 (0.4–1.03) 0.06 0.57 (0.34–0.96) 0.03 0.84 (0.43–1.65) 0.61 0.68 (0.33–1.38) 0.28
Age (y) — 0.96 (0.94–0.97) ,0.0001 0.95 (0.93–0.97) ,0.0001 0.96 (0.94–0.98) 0.0007 0.99 (0.97–1.01) 0.31
Anatomic site Trunk 1 (Reference) ,0.0001 1 (Reference) ,0.0001 1 (Reference) 0.18 1 (Reference) 0.004
Face/scalp 0.24 (0.12–0.5) 0.0001 0.17 (0.08–0.37) ,0.0001 0.66 (0.21–2.1) 0.48 0.25 (0.08–0.8) 0.02
Upper extremity 0.32 (0.15–0.69) 0.004 0.32 (0.13–0.78) 0.01 0.31 (0.12–0.82) 0.02 1.05 (0.38–2.91) 0.92
Lower extremity 0.68 (0.35–1.32) 0.26 0.81 (0.36–1.83) 0.61 0.55 (0.23–1.3) 0.17 1.47 (0.54–4.04) 0.45
Acral 0.17 (0.07–0.42) ,0.0001 0.12 (0.05–0.3) ,0.0001 0.47 (0.13–1.75) 0.26 0.26 (0.07–0.87) 0.03
Thickness (mm) — 0.75 (0.47–1.19) 0.22 0.76 (0.46–1.25) 0.28 0.71 (0.34–1.49) 0.36 0.98 (0.51–1.91) 0.96
aAs opposed to the other variables tested, for scatter the odds for BRAF mutation increased in a nonlinear fashion, with a dramatic increase in odds of being BRAF mutant from cases with
no scatter (score 0) to slight scatter (score 1). To address this nonlinearity, we also calculated higher order polynomial terms. Note that in the case of scatter the linear term can no longer
be interpreted directly as mean OR per incremental unit as exemplified for nesting in the results section.
bOR is calculated per decimal point increment. For ordinal and continuous variables, the OR is displayed as mean OR per incremental unit, for categorical variables it is compared to a
reference.
CI, confidence interval.
doi:10.1371/journal.pmed.0050120.t003
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Morphogenetic Correlation of Melanomapresence or absence of ulceration. In addition to a better
prognosis, the group that, on the basis of their age, was more
likely to have a BRAF mutant melanoma more frequently
presented with metastases to regional nodes; whereas patients
that, on the basis of their age, were less likely to have a BRAF
mutant melanoma tended to have either localized or systemic
metastases (Table S8).
Discussion
In this study we demonstrate that histopathological
features of the primary tumor, many of which have been
part of the WHO classiﬁcation, provide substantial informa-
tion on the mutation status of an important melanoma gene,
BRAF. We found that phenotypic features such as increased
upward scatter and nest formation of intraepidermal
melanocytes; thickening of the involved epidermis; sharp
demarcation from the surrounding skin; as well as the
presence of a larger, rounder, and more pigmented tumor
cells were distinguishing features of melanomas with BRAF
mutation. This ﬁnding suggests that further research will
reveal additional phenotypic associations with other genetic
factors, including both germ line constitution of the patient
and the somatic alterations in the tumor. In general it is not
to be expected that single morphological parameters will be
associated with individual genetic factors since it is likely that
there will be interactions, or partial or functional redun-
dancy, among them.
Results of genotype-phenotype studies can be applied in
two directions. Starting with the genetics, the resulting
phenotypes may allow generation of hypotheses concerning
the function of a genetic factor. For example, our observation
of increased melanin pigment in the tumor cells in
melanomas with BRAF mutations is in line with recent
reports of cooperation between BRAF and MITF in melano-
ma development. MITF is an important transcriptional
regulator of pigmentation that is ampliﬁed in a subset of
melanomas and cooperates with BRAF in transforming
immortalized human melanocytes [27]. A link between BRAF
and pigmentation is further supported by a recent inde-
pendent observation that BRAF-mutant melanomas are also
more pigmented macroscopically [28]. Our study also
identiﬁed strong associations between upward scatter of
intraepidermal melanocytes and formation of nests and
BRAF mutation. Upward scatter is unlikely to be entirely
attributable to BRAF mutations, as scatter is typically absent
in nevi, many of which have BRAF mutations [29], suggesting
that other genes cooperating with BRAF may be involved. By
contrast, many nevi also show melanocytes arranged in nests
and are sharply circumscribed, features that are also more
frequent in BRAF-mutant melanomas. Studies to determine
which of the features found here to be associated with BRAF
mutant melanomas show similar genotype-phenotype associ-
ations in nevi are currently underway.
In the other direction, phenotypic characteristics that are
conventionally assessed in the clinic can be used to develop a
practical classiﬁcation system in which the classes are
genetically homogeneous, and thus more likely to provide
information relevant to patient management. Such a system
may provide valuable, outcome-related information from its
classes even before the genetic factors of each class are
completely understood. Such a classiﬁcation system is likely
Figure 3. Prediction Algorithms of BRAF Mutation
Prediction trees for BRAF mutation status with morphologic variables (A) or variables in the Southern German Tumor Registry (B).
(A) Terminal nodes display heatmaps showing samples by mutation status, ordered and coded as in Figure 2A.
(B) The prediction tree for BRAF mutation using the variables of age, sex, body site, and WHO type also recorded in melanoma registries identifies an
age cutoff of 55 y as the single best predictor of BRAF mutation status. Kaplan Meier survival analysis from the Southern German Tumor Registry shows
a significant (p , 0.0001) decrease in survival when stratified by this age cutoff.
doi:10.1371/journal.pmed.0050120.g003
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practicability and interobserver reproducibility of the cri-
teria that we deﬁned need to be assessed in a clinical setting
and the classiﬁcation algorithms validated on independent
cohorts of cases. Such efforts have been initiated and shown
good to excellent interobserver agreements in scoring the
features used in this study among expert pathologists (to be
published separately).
Among the few variables in our study that overlapped with
data recorded in large patient registries, age was the variable
that best predicted BRAF status. A strong association between
patient age at diagnosis and BRAF mutation status has been
reported previously by us and others [11,28,30,31]. Using the
age cutoff of 55 y determined in our experimental cohort, we
found a signiﬁcant difference in disease-speciﬁc and relapse-
free (unpublished data) survival in an independent clinical
cohort of 4,785 patients. Several previous studies including
our own [11,30,32–36] have not found signiﬁcant survival
differences between melanomas with and without BRAF
mutation. However, the numbers of patients in these studies
are comparably small, and this simple cutoff may be reﬂecting
currently unknown genetic effects that interact with or
substitute for BRAF mutations, and thus reveal signiﬁcantly
different clinical behavior. Future studies will be required to
better understand the factors involved in this survival
difference, hopefully resulting in improved ability to predict
the future course of a particular tumor.
The presence of NRAS mutations was not strongly
associated with the phenotypic measurements we performed.
In the univariate analysis the majority of the OR point
estimates for association with NRAS mutation are close to
one, and so if true associations are present we would expect
them to be much weaker than for BRAF. Multivariate analyses
did not signiﬁcantly enhance the prediction power. This
dissimilarity could reﬂect differences in signaling between
BRAF and NRAS, with NRAS having more pleiotropic effects.
Larger numbers of cases and additional knowledge of
equivalent genetic alterations in melanomas without BRAF
and NRAS mutations are required to evaluate whether some
of the features used here and/or others can further increase
the discrimination between genetically deﬁned subtypes. We
have recently described activation of KIT by mutation and/or
copy number increases in mucosal, acral, and CSD melano-
mas [13]. Too little tissue or DNA was left from the current
cohort of cases to test for associations between KIT
aberrations and any of our features.
Disease classiﬁcation evolves from descriptions of a
combination of symptoms (syndromes), to more reﬁned
deﬁnitions that integrate underlying causes. The increase in
knowledge of underlying causative genetic alterations in
melanoma offers an opportunity to reassess the syndromic
classiﬁcation scheme that emerged from the Sydney classi-
ﬁcation [3] and its revision [4] into the current WHO
classiﬁcation. The genotype-phenotype correlations discov-
ered in our study testify to the intuition of the originators of
the morphological classiﬁcation scheme. The observation that
simple combinations of features could predict BRAF muta-
tion status independent of, and even within WHO subtypes,
indicates that the morphological criteria we used can be
employed to reﬁne the existing classiﬁcation, providing an
opportunity to identify disease subsets that are genetically
more homogenous. Our result represents but one step
towards improved classiﬁcation, and we expect it to be
modiﬁed in light of future discoveries.
In the distant future when genetic knowledge is complete
and targeted therapeutic options are numerous, the appro-
priate clinical work up of a patient is likely to be quite
different from current practice. While initial diagnosis and
aspects of staging will require histopathology, more subtle
distinctions will employ molecular analysis. Reaching this
goal requires following a complex, uncertain path of
incremental advances built on new discoveries and continu-
ous reﬁnement of perceived relationships among disparate
types of knowledge. Here we have investigated the relation-
ship of elementary histopathological characteristics of mel-
anomas to the mutation status of two genes, BRAF and NRAS.
A strong relationship was found for the ﬁrst but not for the
second. As more studies are performed, additional strong
genotype-phenotype relationships may be found, more subtle
effects of genetic interactions and complementation may be
revealed, and consequences of these factors for clinical
behavior of individual tumors may be elucidated. As this
process unfolds, phenotypic characteristics will become
progressively more useful as surrogates for missing genetic
knowledge. Thus development of a melanoma classiﬁcation
system that combines analysis of known genetic factors with
histopathology may produce a clinically powerful method for
managing individual patients and guiding research in the
immediate future.
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Morphogenetic Correlation of MelanomaEditors’ Summary
Background. Skin cancers—the most commonly diagnosed cancers
worldwide—are usually caused by exposure to ultraviolet (UV) radiation
in sunlight. UV radiation damages the DNA in skin cells and can
introduce permanent genetic changes (mutations) into the skin cells that
allow them to divide uncontrollably to form a tumor, a disorganized
mass of cells. Because there are many different cell types in the skin,
there are many types of skin cancer. The most dangerous type—
melanoma—develops when genetic changes occur in melanocytes, the
cells that produce the skin pigment melanin. Although only 4% of skin
cancers are melanomas, 80% of skin cancer deaths are caused by
melanomas. The first signs of a melanoma are often a change in the
appearance or size of a mole (a pigmented skin blemish that is also
called a nevus) or a newly arising pigmented lesion that looks different
from the other moles (an ‘‘ugly duckling’’). If this early sign is noticed
and the melanoma is diagnosed before it has spread from the skin into
other parts of the body, surgery can sometimes provide a cure. But, for
more advanced melanomas, the outlook is generally poor. Although
radiation therapy, chemotherapy, or immunotherapy (drugs that
stimulate the immune system to kill the cancer cells) can prolong the
life expectancy of some patients, these treatments often fail to remove
all of the cancer cells.
Why Was This Study Done? Now, however, scientists have identified
some of the genetic alterations that cause melanoma. For example, they
know that many melanomas carry mutations in either the BRAF gene or
the NRAS gene, and that the proteins made from these mutated genes
(‘‘oncogenes’’) help cancer cells to grow uncontrollably. The hope is that
targeted drugs designed to block the activity of oncogenic BRAF or NRAS
might stop the growth of those melanomas that make these altered
proteins. But how can the patients with these specific tumors be
identified in the clinic? The expression of altered proteins is likely to
affect the microscopic growth patterns (‘‘histomorphology’’) of melano-
mas. However, the current histomorphology-based classification system
for melanomas, which distinguishes four main types of melanoma, does
not help clinicians choose the best treatment for their patients. In this
study, the researchers have tried to improve melanoma classification by
looking for correlations between histomorphological features and
genetic alterations in a large collection of melanomas.
What Did the Researchers Do and Find? The researchers examined
several histomorphological features in more than 300 melanoma
samples and used statistical methods to correlate these features with
the mutation status of BRAF and NRAS in the tumors. They found that
some individual histomorphological features were strongly associated
with the BRAF (but not the NRAS) mutation status of the tumors. For
example, melanomas with BRAF mutations had more melanocytes in the
upper layers of the epidermis (the outermost layer of the skin) than did
those without BRAF mutations (melanocytes usually live at the bottom of
the epidermis). Then, by combining several individual histomorpholog-
ical features, the researchers built a model that correctly predicted the
BRAF mutation status of more than 90% of the melanomas. They also
found that, among the variables routinely recorded in cancer registries,
being younger than 55 years old was the single most predictive factor for
BRAF mutations. Finally, in another large group of patients with
melanoma, the researchers found that those patients predicted to have
a BRAF mutation on the basis of their age survived longer than those
patients predicted not to have a BRAF mutation using the same criterion.
What Do These Findings Mean? These findings suggest that an
improved classification of melanomas that combines an analysis of
known genetic factors with histomorphological features might divide
melanomas into subgroups that are likely to differ in terms of their
clinical outcome and responses to targeted therapies when they become
available. Additional studies are needed to investigate whether the
histomorphological features identified here can be readily assessed in
clinical settings and whether different observers will agree on the scoring
of these features. The classification model defined by the researchers
also needs to be validated and refined in independent groups of
patients. Nevertheless, these findings represent an important first step
toward helping clinicians improve outcomes for patients with melano-
ma.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050120.
  A related PLoS Medicine Research in Translation article is available
  The MedlinePlus encyclopedia provides information for patients about
melanoma
  The US National Cancer Institute provides information for patients and
health professionals about melanoma (in English and Spanish)
  Cancer Research UK also provides detailed information about the
causes, diagnosis, and treatment of melanoma
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